eltrombopag + lopinavir + ritonavir

This entry describes the **combination of eltrombopag, lopinavir, and ritonavir**. Eltrombopag is an orally bioavailable small molecule that acts as a thrombopoietin receptor agonist to stimulate platelet production, primarily used for thrombocytopenia in chronic idiopathic thrombocytopenic purpura and considered for thrombocytopenia related to HIV and HCV infection[1][5]. Lopinavir and ritonavir are combined antiretroviral protease inhibitors principally used in HIV treatment, with ritonavir functioning mainly as a pharmacokinetic booster (CYP3A inhibitor) to increase lopinavir levels[2][3][4][6]. The combination has been clinically evaluated for pharmacokinetic interactions, with evidence showing that lopinavir/ritonavir slightly reduces eltrombopag exposure by inducing its metabolism via CYP1A2 and UGT pathways, but does not significantly change lopinavir/ritonavir exposure[1][5]. This combination may be relevant in the setting of HIV-associated thrombocytopenia.

Brand names

RevoladePromactaKaletra

Other names

eltrombopag olamine